BEI
HRTX icon

Benjamin Edwards Inc’s Heron Therapeutics HRTX Stock Holding History

Benjamin Edwards Inc’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$4K – 1140
2024
Q2 		$4K Hold
1,000
– – ﹤0.01% 648
2024
Q1 		$3K Buy
1,000
+181
+22% +$455 ﹤0.01% 685
2023
Q4 		$1K Sell
819
-718
-47% -$791 ﹤0.01% 629
2023
Q3 		$2K Hold
1,537
– – ﹤0.01% 618
2023
Q2 		$2K Sell
1,537
-189
-11% -$337 ﹤0.01% 641
2023
Q1 		$3K Sell
1,726
-347
-17% -$869 ﹤0.01% 648
2022
Q4 		$5K Hold
2,073
– – ﹤0.01% 636
2022
Q3 		$9K Hold
2,073
– – ﹤0.01% 567
2022
Q2 		$6K Buy
2,073
+578
+39% +$2.32K ﹤0.01% 613
2022
Q1 		$9K Buy
1,495
+1,254
+520% +$9.18K ﹤0.01% 613
2021
Q4 		$2K Buy
+241
New +$2.46K ﹤0.01% 677

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Benjamin Edwards Inc's HRTX Position: Q3 2024 in Review

Benjamin Edwards Inc sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 1,000 shares — an estimated $4K sold.

Benjamin Edwards Inc first reported a position in HRTX in Q4 2021 and held it in 11 quarters. The position peaked at $9K in Q3 2022. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Benjamin Edwards Inc reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Benjamin Edwards Inc sold 1,000 Heron Therapeutics shares in Q3 2024, an estimated $4K.
  • Benjamin Edwards Inc first reported a position in Heron Therapeutics in Q4 2021 and held it in 11 quarters.
  • Benjamin Edwards Inc's Heron Therapeutics position peaked at $9K in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Benjamin Edwards Inc's 13F filing for Q3 2024, filed 14 Nov 2024.